Literature DB >> 22220885

Cytotoxicity and hydrolysis of trans-Ti(IV) complexes of salen ligands: structure-activity relationship studies.

Avia Tzubery1, Edit Y Tshuva.   

Abstract

Eleven bis(dimethylphenolato) Ti(IV) complexes of salen ligands with different steric and electronic properties due to different aromatic substituents at the ortho and para positions are reported, and their cytotoxicity toward HT-29 and OVCAR-1 cells and its dependence on hydrolytic behavior are discussed. Eight complexes of this series were analyzed by X-ray crystallography, confirming the trans geometry of the labile ligands with otherwise relatively similar coordination features to those of cis-salan analogues. Relatively high and similar hydrolytic stability is observed for all complexes, with t(1/2) values for labile ligand hydrolysis of 2-11 h in 10% D(2)O solutions. In contrast, varying cytotoxicities were achieved, identifying selected members as the first trans-Ti(IV) complexes reported as anticancer agents. Steric bulk all around the complex diminished the activity, where a complex with no aromatic substitutions is especially active and complexes substituted particularly at the ortho positions are mostly inactive, including ortho-halogenated and ortho-tert-butylated, with one exception of the ortho-methoxylated complex demonstrating appreciable activity. In contrast, para-halogenation provided the complexes of highest cytotoxic activity in this series (IC(50) as low as 1.0 ± 0.3 μM), with activity exceeding that of cisplatin by up to 15-fold. Reaction of a representative complex with ortho-catechol yielded a "cis"-Ti(IV) complex following rearrangement of the salen ligand on the metal center, with highly similar coordination features and geometry to those of the catecholato salan analogues, suggesting that the complexes operate by similar mechanisms and rearrangement of the salen ligand may occur upon introduction of a suitable chelating target. In additional cytotoxicity measurements, a salen complex was preincubated in the biological medium for varying periods prior to cell addition, revealing that marked cytotoxicity of the salen complex is retained for longer preincubation periods relative to known Ti(IV) complexes, suggesting that the hydrolysis products may also induce cytotoxic effects, thus reducing stability concerns.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22220885     DOI: 10.1021/ic202092u

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  6 in total

1.  Anticancer metal complexes: synthesis and cytotoxicity evaluation by the MTT assay.

Authors:  Nitzan Ganot; Sigalit Meker; Lilia Reytman; Avia Tzubery; Edit Y Tshuva
Journal:  J Vis Exp       Date:  2013-11-10       Impact factor: 1.355

2.  Synthesis of asymmetrical diaminobis(alkoxo)-bisphenol compounds and their C1-symmetrical mono-ligated titanium(iv) complexes as highly stable highly active antitumor compounds.

Authors:  Gilad Nahari; Edit Y Tshuva
Journal:  Dalton Trans       Date:  2021-05-04       Impact factor: 4.390

3.  Titanium Tackles the Endoplasmic Reticulum: A First Genomic Study on a Titanium Anticancer Metallodrug.

Authors:  Maya Miller; Anna Mellul; Maya Braun; Dana Sherill-Rofe; Emiliano Cohen; Zohar Shpilt; Irene Unterman; Ori Braitbard; Jacob Hochman; Edit Y Tshuva; Yuval Tabach
Journal:  iScience       Date:  2020-06-12

4.  Racemic vs. enantiopure inert Ti(iv) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines.

Authors:  Maya Miller; Edit Y Tshuva
Journal:  RSC Adv       Date:  2018-11-27       Impact factor: 4.036

5.  3-Bromo-2-hy-droxy-benzaldehyde.

Authors:  Jessica B Metlay; Joseph M Tanski
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-07-18

6.  In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum Drugs.

Authors:  Nitzan Ganot; Ori Briaitbard; Asaad Gammal; Joseph Tam; Jacob Hochman; Edit Y Tshuva
Journal:  ChemMedChem       Date:  2018-10-19       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.